Search Results - "Simon, Jakub K."

Applications of nanotechnology for immunology by Smith, Douglas M., Simon, Jakub K., Baker Jr, James R.

“…Key Points Nanotechnology makes use of the unique properties of objects that function as a unit within the overall size range of 1 to 1,000 nanometres, which…”
Get full text

Immunology of gut mucosal vaccines by Pasetti, Marcela F., Simon, Jakub K., Sztein, Marcelo B., Levine, Myron M.

“…Understanding the mechanisms underlying the induction of immunity in the gastrointestinal mucosa following oral immunization and the cross‐talk between mucosal…”
Get full text

Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates by Gunn, Bronwyn M., McNamara, Ryan P., Wood, Lianna, Taylor, Sabian, Devadhasan, Anush, Guo, Wenyu, Das, Jishnu, Nilsson, Avlant, Shurtleff, Amy, Dubey, Sheri, Eichberg, Michael, Suscovich, Todd J., Saphire, Erica Ollmann, Lauffenburger, Douglas, Coller, Beth-Ann, Simon, Jakub K., Alter, Galit

“…The 2013 Ebola epidemic in Central and West Africa heralded the emergence of wide-spread, highly pathogenic viruses. The successful recombinant vector vaccine…”
Get full text

Development of Pandemic Vaccines: ERVEBO Case Study by Wolf, Jayanthi, Jannat, Risat, Dubey, Sheri, Troth, Sean, Onorato, Matthew T, Coller, Beth-Ann, Hanson, Mary E, Simon, Jakub K

“…Preventative vaccines are considered one of the most cost-effective and efficient means to contain outbreaks and prevent pandemics. However, the requirements…”
Get full text

rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment by Monath, Thomas P, Fast, Patricia E, Modjarrad, Kayvon, Clarke, David K, Martin, Brian K, Fusco, Joan, Nichols, Richard, Heppner, D Gray, Simon, Jakub K, Dubey, Sheri, Troth, Sean P, Wolf, Jayanthi, Singh, Vidisha, Coller, Beth-Ann, Robertson, James S

“…The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety and characteristics of live, recombinant viral…”
Get full text

A clinically parameterized mathematical model of Shigella immunity to inform vaccine design by Davis, Courtney L, Wahid, Rezwanul, Toapanta, Franklin R, Simon, Jakub K, Sztein, Marcelo B

“…We refine and clinically parameterize a mathematical model of the humoral immune response against Shigella, a diarrheal bacteria that infects 80-165 million…”
Get full text

Correction: A clinically parameterized mathematical model of Shigella immunity to inform vaccine design by Davis, Courtney L, Wahid, Rezwanul, Toapanta, Franklin R, Simon, Jakub K, Sztein, Marcelo B

“…[This corrects the article DOI: 10.1371/journal.pone.0189571.]…”
Get full text

Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers by Islam, Kamrul, Hossain, Motaher, Kelly, Meagan, Mayo Smith, Leslie M, Charles, Richelle C, Bhuiyan, Taufiqur Rahman, Kováč, Pavol, Xu, Peng, LaRocque, Regina C, Calderwood, Stephen B, Simon, Jakub K, Chen, Wilbur H, Haney, Douglas, Lock, Michael, Lyon, Caroline E, Kirkpatrick, Beth D, Cohen, Mitchell, Levine, Myron M, Gurwith, Marc, Harris, Jason B, Qadri, Firdausi, Ryan, Edward T

“…Cholera is an acute voluminous dehydrating diarrheal disease caused by toxigenic strains of Vibrio cholerae O1 and occasionally O139. A growing body of…”
Get full text

Applying mathematical tools to accelerate vaccine development: modeling Shigella immune dynamics by Davis, Courtney L, Wahid, Rezwanul, Toapanta, Franklin R, Simon, Jakub K, Sztein, Marcelo B, Levy, Doron

“…We establish a mathematical framework for studying immune interactions with Shigella, a bacteria that kills over one million people worldwide every year. The…”
Get full text

Gut-Homing Conventional Plasmablasts and CD27(-) Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in Humans by Toapanta, Franklin R, Simon, Jakub K, Barry, Eileen M, Pasetti, Marcela F, Levine, Myron M, Kotloff, Karen L, Sztein, Marcelo B

“…Currently, there is no licensed Shigella vaccine; however, various promising live-attenuated vaccine candidates have emerged, including CVD1208S (ΔguaBA, Δset,…”
Get full text

Mucosal IgA Responses in Healthy Adult Volunteers following Intranasal Spray Delivery of a Live Attenuated Measles Vaccine by Simon, Jakub K, Ramirez, Karina, Cuberos, Lilian, Campbell, James D, Viret, Jean F, Muñoz, Alma, Lagos, Rosanna, Levine, Myron M, Pasetti, Marcela F

“…Classifications Services CVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor by Chen, Wilbur H, Cohen, Mitchell B, Kirkpatrick, Beth D, Brady, Rebecca C, Galloway, David, Gurwith, Marc, Hall, Robert H, Kessler, Robert A, Lock, Michael, Haney, Douglas, Lyon, Caroline E, Pasetti, Marcela F, Simon, Jakub K, Szabo, Flora, Tennant, Sharon, Levine, Myron M

“…No licensed cholera vaccine is presently available in the United States. Cholera vaccines available in other countries require 2 spaced doses. A single-dose…”
Get full text

Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial by Wassil, James, Sisti, Maggie, Fairman, Jeff, Davis, Matthew, Fierro, Carlos, Bennett, Sean, Johnson, Derek, Migone, Thi-Sau, Nguyen, Kien, Sauer, Paul, Currie, Michelle, Iki, Sam, Simon, Jakub K

“…Despite substantial reductions in pneumococcal disease with the availability of pneumococcal conjugate vaccines, a significant burden of pneumococcal disease…”
Get full text

Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults by Halperin, Scott A, Das, Rituparna, Onorato, Matthew T, Liu, Kenneth, Martin, Jason, Grant-Klein, Rebecca J, Nichols, Rick, Coller, Beth-Ann, Helmond, Frans A, Simon, Jakub K

“…Abstract Background This double-blind study assessed immunogenicity, lot consistency, and safety of recombinant vesicular stomatitis virus-Zaire Ebola virus…”
Get full text

Serostatus cutoff levels and fold increase to define seroresponse to recombinant vesicular stomatitis virus – Zaire Ebola virus envelope glycoprotein vaccine: An evidence-based analysis by Antonello, Joseph, Grant-Klein, Rebecca J., Nichols, Rick, Kennedy, Stephen B., Dubey, Sheri, Simon, Jakub K.

“…•Antibody response correlating with vaccination was used to define seroresponse.•P-values from Fisher’s exact test were used to compare definitions of…”
Get full text

Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults by Halperin, Scott A., Arribas, Jose R., Rupp, Richard, Andrews, Charles P., Chu, Laurence, Das, Rituparna, Simon, Jakub K., Onorato, Matthew T., Liu, Kenneth, Martin, Jason, Helmond, Frans A.

“…Background. This study (NCT02503202) evaluated the safety of recombinant vesicular stomatitis virus–Zaire Ebola virus envelope glycoprotein vaccine…”
Get full text

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV by Mohapi, Lerato, Pinedo, Yvett, Osiyemi, Olayemi, Supparatpinyo, Khuanchai, Ratanasuwan, Winai, Molina, Jean-Michel, Dagan, Ron, Tamms, Gretchen, Sterling, Tina, Zhang, Ying, Pedley, Alison, Hartzel, Jon, Kan, Yanqing, Hurtado, Kim, Musey, Luwy, Simon, Jakub K., Buchwald, Ulrike K.

“…To evaluate safety and immunogenicity of V114 [15-valent pneumococcal conjugate vaccine (PCV) containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A,…”
Get full text

Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE) by Simon, Jakub K., Staerke, Nina Breinholt, Hemming-Harlo, Maria, Layle, Stacey, Dagan, Ron, Shekar, Tulin, Pedley, Alison, Jumes, Patricia, Tamms, Gretchen, Sterling, Tina, Musey, Luwy, Buchwald, Ulrike K.

“…•V114 is well tolerated and immunogenic.•V114 has a safety profile that is consistent across manufacturing lots.•V114 elicits an equivalent immune response…”
Get full text

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials by Simon, Jakub K., Kennedy, Stephen B., Mahon, Barbara E., Dubey, Sheri A., Grant-Klein, Rebecca J., Liu, Ken, Hartzel, Jonathan, Coller, Beth-Ann G., Welebob, Carolee, Hanson, Mary E., Grais, Rebecca F.

“…•In 3 phase 2/3 trials in Africa, vaccination with ERVEBO™ yielded robust immune responses.•Baseline seropositive participants had higher binding antibody…”
Get full text

Using the power law model to predict the long-term persistence and duration of detectable hepatitis A antibody after receipt of hepatitis A vaccine (VAQTA™) by Martin, Jason C., Petrecz, Maria L., Stek, Jon E., Simon, Jakub K., Goveia, Michelle G., Klopfer, Stephanie O.

“…VAQTA™ (Hepatitis A Vaccine, inactivated [HAVi]; Merck & Co., Inc., Kenilworth, NJ, USA) is currently licensed for prevention of disease caused by hepatitis A…”
Get full text